Triple-negative metaplastic breast cancer: treatment and prognosis by type of surgery

被引:1
|
作者
Hu, Jin [1 ]
Dong, Fang [1 ]
Zhang, Yanting [2 ]
Shen, Jian [3 ]
Ming, Jie [1 ]
Huang, Tao [1 ]
机构
[1] Huazhong Univ Sci & Technol, Dept Breast & Thyroid Surg, Tongji Med Coll, Union Hosp, Wuhan 430022, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Ultrasound, Wuhan 430022, Hubei, Peoples R China
[3] Huazhong Univ Sci & Technol, Dept Pancreat Surg, Union Hosp, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China
来源
关键词
Metaplastic; breast cancer; surgery; prognosis; inverse probability weights; CARCINOMA;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The role of surgery type in the prognosis of triple-negative metaplastic breast cancer (TNMBC) patients remains controversial. Our study was designed to assess the role of surgery type in patient outcomes. Materials and methods: Data from the Surveillance, Epidemiology, and End Results database were extracted to analyze patients with TN-MBC between 2010 and 2016. Kaplan-Meier analyses and multivariate Cox proportional models were used to estimate the prognoses. Results: We included 1,146 patients with a median follow-up time of 26 months (range 1-83 months). 470 (41.0%), 369 (32.2%), 244 (21.3%), and 63 (5.5%) patients underwent breast-conserving surgery (BCS), total mastectomy (TM), radical mastectomy, or no surgery. With the multivariate Cox analysis, the prognosis was related to age, TNM stage, and surgery type. With the Kaplan-Meier analysis, the more radical the operation, the worse the prognosis for the patients in the entire cohort. Within stage I-III disease, the best prognoses were observed in the patients undergoing BCS, followed by TM and radical mastectomy. The adjusted survival analysis showed that the prognoses of the patients undergoing BCS were better than the prognoses of the patients undergoing TM. Within stage IV disease, the patients who underwent an operation had a better prognosis regardless of the mode. Conclusion: Patients undergoing BCS had the best prognoses among the patients with early and locally advanced TN-MBC. This improves our understanding of the clinicopathological and prognostic features of this rare entity but also provides more convincing therapeutic guidelines for TN-MBC.
引用
收藏
页码:11689 / 11696
页数:8
相关论文
共 50 条
  • [21] Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer
    Paolo Tarantino
    Julieta Leone
    Carlos T. Vallejo
    Rachel A. Freedman
    Adrienne G. Waks
    Olga Martínez-Sáez
    Ana Garrido-Castro
    Filipa Lynce
    Nabihah Tayob
    Nancy U. Lin
    Sara M. Tolaney
    Jose P. Leone
    [J]. npj Breast Cancer, 10
  • [22] Metaplastic carcinoma with extensive dendritic cell differentiation: a previously unrecognised type of triple-negative breast cancer
    Cesinaro, A. M.
    Maiorana, A.
    Ficarra, G.
    Pruneri, G.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (11) : 2531 - U190
  • [23] Nanomedicine for the treatment of triple-negative breast cancer
    Kutty, Rajaletchumy Veloo
    Leong, David Tai Wei
    Feng, Si-Shen
    [J]. NANOMEDICINE, 2014, 9 (05) : 561 - 564
  • [24] Targeted Treatment of Triple-Negative Breast Cancer
    Young, Joanna A.
    Tan, Antoinette R.
    [J]. CANCER JOURNAL, 2021, 27 (01): : 50 - 58
  • [25] Treatment Horizons for Triple-negative Breast Cancer
    Yeo, W.
    [J]. HONG KONG JOURNAL OF RADIOLOGY, 2015, 18 (02): : 111 - 118
  • [26] Postneoadjuvant treatment for triple-negative breast cancer
    Trapani, Dario
    Ferraro, Emanuela
    Giugliano, Federica
    Bielo, Luca Boscolo
    Curigliano, Giuseppe
    Burstein, Harold J.
    [J]. CURRENT OPINION IN ONCOLOGY, 2022, 34 (06) : 623 - 634
  • [27] Local Treatment of Triple-Negative Breast Cancer
    Machiels, Melanie
    Kaidar-Person, Orit
    Rubio, Isabel T.
    Poortmans, Philip
    [J]. CANCER JOURNAL, 2021, 27 (01): : 32 - 40
  • [28] The treatment landscape of triple-negative breast cancer
    Hu, Yi
    Wang, Chen
    Liang, Huishi
    Li, Jie
    Yang, Qiong
    [J]. MEDICAL ONCOLOGY, 2024, 41 (10)
  • [29] Cannabinoids and triple-negative breast cancer treatment
    Dobovisek, Luka
    Borstnar, Simona
    Debeljak, Natasa
    Brezar, Simona Kranjc
    [J]. FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [30] Atezolizumab for the treatment of triple-negative breast cancer
    Heimes, Anne-Sophie
    Schmidt, Marcus
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (01) : 1 - 5